Drug Profile
Research programme: PEP compounds - Peplin Limited
Alternative Names: PEP 006; PEP 008; PEP 010Latest Information Update: 18 Jan 2010
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Class Macrocyclic compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Actinic keratosis; Basal cell cancer; Squamous cell cancer
Most Recent Events
- 18 Jan 2010 Discontinued - Preclinical for Actinic keratosis in USA (Intralesional)
- 18 Jan 2010 Discontinued - Preclinical for Basal cell cancer in USA (Topical)
- 18 Jan 2010 Discontinued - Preclinical for Squamous cell cancer in USA (unspecified route)